Tarsus Pharmaceuticals, Inc. (TARS)

Several events have impacted Tarsus Pharmaceuticals' stock price in the past six months. Tarsus reported Q1 2025 net product sales of $78.3 million for XDEMVY and completed a public equity offering, raising approximately $135 million. The company actively participated in numerous investor conferences. Tarsus reported record-breaking Q2 2025 net product sales of $102.7 million for XDEMVY. The company's stock reached new 52-week and 12-month highs in October 2025. Insider transactions, including significant share sales by a director and the CEO, were reported in September 2025. The stock price of Tarsus Pharmaceuticals, Inc. increased by 66.52% between October 28, 2024, and October 24, 2025.

Tarsus Pharmaceuticals' flagship product, XDEMVY, experiences demand seasonality. The company has acknowledged typical seasonal headwinds, such as summer vacations and holidays, potentially impacting Q3 demand. Tarsus anticipates that direct-to-consumer campaigns and favorable reimbursement dynamics will drive stronger growth in Q4 and beyond, offsetting these seasonal fluctuations. Information regarding demand seasonality for TP-04 and TP-05 is not explicitly available, as these products are still in clinical development.

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies, primarily for eye care in the United States. Their lead product is XDEMVY, the first FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of product candidates, including TP-04 for Ocular Rosacea, TP-05 for the prevention of Lyme disease and community malaria reduction, and lotilaner API to address various diseases in human medicine.

Tarsus Pharmaceuticals is headquartered in Irvine, California, with a primary focus on the United States for eye care therapeutic candidates. They have a partnership for TP-03 (XDEMVY) in Mainland China, Hong Kong, Macau, and Taiwan. Tarsus is exploring global expansion, with potential European regulatory approval for a preservative-free formulation of XDEMVY by 2027 and a prevalence study in Japan planned for 2025.

Tarsus Pharmaceuticals has cultivated a brand reputation centered on revolutionizing patient treatment, particularly in eye care, and advancing a vision for change. The company emphasizes its scientific approach to creating new categories and a distinct culture driven by teamwork, empowerment, and commitment. Tarsus is recognized for its dedication to addressing unmet medical needs and its proactive communication with doctors to better serve patients. There have been no significant negative events impacting Tarsus Pharmaceuticals' brand reputation reported in the past year.

Tarsus Pharmaceuticals is primarily owned by institutional shareholders (109.28%) and Tarsus Pharmaceuticals insiders (38.64%), with a negligible percentage held by retail investors. Major institutional and individual owners include Vivo Capital IX LLC, BlackRock Inc., RTW Investments LP, Paradigm Biocapital Advisors LP, Jennison Associates LLC, Tang Capital Management LLC, Vanguard Group Inc, Morgan Stanley, Janus Henderson Group Plc, Deep Track Capital, LP, and Frazier Life Sciences Management, L.P.